TCS 2210 (CAS 1201916-31-5)

TCS 2210, a potent and selective inhibitor, has garnered significant attention in scientific research, particularly in the field of kinase biology and signal transduction pathways. Its mechanism of action primarily revolves around its ability to inhibit the activity of Bruton′s tyrosine kinase (BTK), a critical enzyme involved in B-cell receptor (BCR) signaling. By targeting BTK, TCS 2210 disrupts downstream signaling cascades, leading to modulation of B-cell activation, proliferation, and differentiation. Research investigations have utilized TCS 2210 to explain the role of BTK signaling in various immune-mediated disorders, including autoimmune diseases and B-cell malignancies. Studies have demonstrated its efficacy in blocking aberrant B-cell activation and proliferation, offering insights into potential strategies for targeting BTK-dependent pathways in disease conditions. Furthermore, TCS 2210 has been instrumental in dissecting the molecular mechanisms underlying BCR signaling and its crosstalk with other signaling pathways, providing a deeper understanding of immune cell function and dysregulation. Its specificity and potency in inhibiting BTK make TCS 2210 a valuable tool for investigating the pathophysiology of immune-related diseases and exploring novel interventions aimed at modulating B-cell signaling.